
Science communication, media relations, strategy and public affairs for European, international and national organisations, conferences and journals
Latest Press Releases
- New drug IACS-6274 shows promise in phase I clinical trial treating patients with advanced ovarian cancerBarcelona, Spain: Patients with advanced, hard-to-treat ovarian cancer have responded well to treatment with a drug called IACS-6274 when combined with the targeted therapy bevacizumab and paclitaxel chemotherapy. Results from a phase I clinical trial in… Read more: New drug IACS-6274 shows promise in phase I clinical trial treating patients with advanced ovarian cancer
- Antibody-drug conjugate designed to target tumour ‘scaffolding’ produces positive results in phase I head and neck cancer trialBarcelona, Spain: An antibody-drug conjugate (ADC), called micvotabart pelidotin, or MICVO, has produced positive results in an early trial with head and neck cancer patients. The results, presented at the 38th EORTC-NCI-AACR Symposium on Molecular Targets… Read more: Antibody-drug conjugate designed to target tumour ‘scaffolding’ produces positive results in phase I head and neck cancer trial
- Antibody-drug conjugate shows promising early results in phase I trial in sarcoma patientsBarcelona, Spain: An antibody-drug conjugate, a type of drug that targets and enters cancer cells like a Trojan Horse, has shown promising early results across diverse types of soft tissue sarcoma in a phase I trial.… Read more: Antibody-drug conjugate shows promising early results in phase I trial in sarcoma patients
- People with long Covid have drastically different microbiome in their lungs and mouthA study of more than 700 people has shown that those with long Covid have distinct differences in the mix of bacteria that live in their mouths and lungs, according to a study published in the… Read more: People with long Covid have drastically different microbiome in their lungs and mouth